You are here:

Archived: omalizumab 150mg powder and solvent for injection (Xolair)

Advice

Following a resubmission.

Omalizumab (Xolair®) is not recommended for use within NHS Scotland as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe persistent allergic asthma.

The economic case has not been demonstrated.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: omalizumab 150mg powder and solvent for injection (Xolair)
SMC Drug ID: 259/06
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Asthma
BNF Category:
Submission Type: Resubmission
Status: Superseded
Date Advice Published: 15 January 2007

Current Advice

Resubmission 8 October 2007

Archived Advice

Full submission 12 June 2006

Back